Por supuesto, añadimos a todo este ritual de cuidado de nuestro cutis un buen sérum para hidratar, mascarillas faciales y muchos otros productos, pero, ¿por qué no cuidamos con tanto detalle ...

Citi analyst Samantha Semenkow initiated coverage of BioAge Labs (BIOA) with a Buy rating and $45 price target BioAge is a clinical-staged biotech focused on advancing therapies for metabolic ...

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...

BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy September 26, 2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

Jefferies initiated coverage of BioAge Labs (BIOA) with a Buy rating and $42 price target BioAge is a clinical stage biotech focusing on metabolic diseases, the analyst tells investors in a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting ...